AMSTERDAM and LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment ...
Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a synthetic lethal program in a deal worth more than 500 million euros ($570 ...
Naarden, the Netherlands and Stevenage, UK, 01 October 2025 – Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, today announces the ...
Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer therapies for tumours that rely on the alternative lengthening of telomeres ...
Boehringer Ingelheim and Tessellate Bio have entered into a partnership worth over €500m to develop oral precision medicines for hard-to-treat cancers. The research collaboration and global licence ...
With an initial €8 million (US$8.4 million) in seed funding in the bank, Tessellate Bio has emerged from stealth to tackle cancers that rely on the less well explored synthetic lethality mechanism of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback